| Autor: |
Antoinette AY; Cornell University, Ithaca, NY, USA., Ziemian SN; Cornell University, Ithaca, NY, USA., Brown AR; Cornell University, Ithaca, NY, USA., Hudson EB; Cornell University, Ithaca, NY, USA., Chlebek C; Cornell University, Ithaca, NY, USA., Wright TM; Hospital for Special Surgery, New York, NY, USA., Goldring SR; Hospital for Special Surgery, New York, NY, USA., Goldring MB; Hospital for Special Surgery, New York, NY, USA., Otero M; Hospital for Special Surgery, New York, NY, USA.; Weill Cornell Medicine, New York, NY, USA., van der Meulen MCH; Cornell University, Ithaca, NY, USA.; Hospital for Special Surgery, New York, NY, USA. |
| Abstrakt: |
Osteoarthritis (OA) treatment is limited by the lack of effective nonsurgical interventions to slow disease progression. Here, we examined the contributions of the subchondral bone properties to OA development. We used parathyroid hormone (PTH) to modulate bone mass before OA initiation and alendronate (ALN) to inhibit bone remodeling during OA progression. We examined the spatiotemporal progression of joint damage by combining histopathological and transcriptomic analyses across joint tissues. The additive effect of PTH pretreatment before OA initiation and ALN treatment during OA progression most effectively attenuated load-induced OA pathology. Individually, PTH directly improved cartilage health and slowed the development of cartilage damage, whereas ALN primarily attenuated subchondral bone changes associated with OA progression. Joint damage reflected early transcriptomic changes. With both treatments, the structural changes were associated with early modulation of immunoregulation and immunoresponse pathways that may contribute to disease mechanisms. Overall, our results demonstrate the potential of subchondral bone-modifying therapies to slow the progression of OA. |
